Skip to main content

Advertisement

Table 1 Distribution of sample size and disease activity scores in the low and high activity groups of each immune-mediated inflammatory disease (IMID) after quality control

From: Urine metabolome profiling of immune-mediated inflammatory diseases

IMID Disease activity score Discovery cohort Validation cohort
Low activitya High activitya Low activitya High activitya
CD Harvey-Bradshaw Index [71] 154 (0.0) 45 (7.0) 100 (0.0) 100 (9.0)
UC Lichtiger Score [72] 124 (0.0) 81 (6.0) 99 (0.0) 98 (5.0)
RA Disease Activity Score 28 [73] 114 (1.7) 127 (5.5) 98 (1.6) 95 (5.6)
PsA Disease Activity Score 28 [73] 97 (1.5) 89 (3.9) 96 (1.5) 96 (4.2)
Ps Psoriasis Area Severity Index [74] 101 (0.0) 84 (14.1) 100 (0.0) 92 (17.5)
SLE Selena-Sledai [75] and BILAG [76] 123 (1.0b) 41 (11.0b) 90 (1.0b) 88 (7.5b)
  1. Description of the sample sizes and median disease activity values in the discovery and validation stages for each IMID (CD, Crohn’s disease; UC, ulcerative colitis; RA, rheumatoid arthritis; PsA, psoriatic arthritis; Ps, psoriasis; SLE, systemic lupus erythematosus)
  2. aNumber of samples (median disease activity values)
  3. bMaximum of Selena-Sledai and BILAG indices of each patient